Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download
A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent | PLOS ONE
![Distribution of patients inside risk groups and OS by standard IPI [8],... | Download Table](https://www.researchgate.net/profile/Santo-Neri/publication/38095873/figure/tbl1/AS:667607128604690@1536181351880/Distribution-of-patients-inside-risk-groups-and-OS-by-standard-IPI-8-R-IPI-3-and_Q640.jpg "Distribution of patients inside risk groups and OS by standard IPI [8],... | Download Table")
Distribution of patients inside risk groups and OS by standard IPI [8],... | Download Table
KoreaMed Synapse
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect
EHA Library - The official digital education library of European Hematology Association (EHA)
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14 | PLOS ONE
MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
Diffuse large B-cell lymphoma: Early patient management | OTT
Response to treatment according to different R-IPI categories | Download Table
Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma | Hematology, Transfusion and Cell Therapy
Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?
The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP | Scientific Reports
Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
Diffuse Large B-Cell Lymphoma: Can We Improve Our Current Approaches to Management?
Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
Non-Hodgkin's and Hodgkin's Lymphoma | Basicmedical Key
The Enhanced International Prognostic Index for Diffuse Large B‐cell Lymphoma | Semantic Scholar
Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect
Diffuse Large B-Cell Lymphoma: Can We Improve Our Current Approaches to Management?
Outcome according to the revised International Prognostic Index (R-IPI)... | Download Scientific Diagram
